Baxter International (BAX)
(Delayed Data from NYSE)
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Zacks News
Henry Schein (HSIC) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Henry Schein (HSIC) sees solid performance by the global Medical and Technology and Value-added Services businesses in Q2.
Becton, Dickinson (BDX) Beats on Q3 Earnings and Revenues
by Zacks Equity Research
Strong contributions from BD Medical and Interventional units drive Becton, Dickinson???s (BDX) fiscal third quarter.
Hill-Rom (HRC) Beats on Q3 Earnings, Tightens '19 Guidance
by Zacks Equity Research
Hill-Rom (HRC) registers a solid year-over-year increase in revenues on robust domestic growth.
Integer Holdings (ITGR) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Higher revenues and strong 2019 outlook benefit Integer Holdings' (ITGR) Q2 earnings.
HMS Holdings (HMSY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Higher revenues, gross margin expansion and raised 2019 outlook benefit HMS Holdings' (HMSY) Q2 earnings.
Intersect (XENT) Q2 Loss Wider Than Estimates, Revenues Miss
by Zacks Equity Research
Intersect ENT's (XENT) lowered revenue guidance for 2019 raises concern.
PRA Health (PRAH) Q2 Earnings Beat, EPS Guidance Narrowed
by Zacks Equity Research
PRA Health (PRAH) slashes 2019 revenue guidance; direct costs surge in second quarter.
Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.
Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.
Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up
by Zacks Equity Research
Globus Medical's (GMED) spine business gains traction from solid worldwide growth in the second quarter.
Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results
by Zacks Equity Research
The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.
Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
We are upbeat about Bio-Rad's (BIO) year-over-year revenue growth within the Clinical Diagnostics segment in Q2.
DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) raises guidance for 2019 adjusted EPS.
DaVita (DVA) Earnings Beat, Revenues Miss Estimates in Q2
by Zacks Equity Research
DaVita (DVA) completes divestment of DMG unit to Optum for $4.34 billion.
Bruker (BRKR) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Bruker (BRKR) registers strong year-over-year revenue growth across all segments and geographies.
Amedisys (AMED) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust year-over-year growth in Medicare and non-Medicare revenues aids Amedisys' (AMED) Home Health and Hospice divisions.
Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) Q1 results benefit from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.
AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Higher revenues, segmental growth and raised 2019 EPS outlook benefit AmerisourceBergen's (ABC) Q3 earnings.
Luminex (LMNX) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Higher revenues and solid performance across System Sales, Consumable Sales and Royalty Revenues benefit Luminex's (LMNX) Q2 earnings. However, gross margin contraction remains a woe.
CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.
ABIOMED (ABMD) Q1 Earnings Top Estimates, Sales Rise in Japan
by Zacks Equity Research
ABIOMED (ABMD) slashes revenue guidance for fiscal 2020.
IDEXX (IDXX) Beats Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
IDEXX's (IDXX) top line in the second quarter gains from strong sales at the CAG business.
Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.